← Leaderboards
Martin S Maron
Tufts Medical Center
$2,511,473
Attributed
$4,387,646
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $782.7K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,387,646 · 3
By mechanism
R01$3,752,347 · 2
K23$635,299 · 1
Top collaborators
- Reza Nezafat5 shared
Most similar at Tufts Medical Center
Same institution · by research overlap
- Iris Z Jaffe$20,757,672
- Michael G Shlipak$18,418,069
- Orlando M Gutierrez$29,690,151
- Joseph Gormley$1,176,039
- Rosina Weber$1,176,039
Others in their field
Top investigators on “Genetic”
- Richard A Gibbs · Baylor College Of Medicine$577,061,667
- Eric S Lander · Whitehead Institute For Biomedical Res$560,806,052
- David R. Weir · University Of Michigan At Ann Arbor$322,225,557
- Richard K. Wilson · Washington University$316,685,275
- Lawrence Corey · Fred Hutchinson Cancer Center$312,182,347
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$302,429,647
Research focus
GeneticNatural HistorySymptomsCardiovascular SystemFunctional DisorderCardiacTissuesImageHypertrophic CardiomyopathyHeart FailureHeart DiseasesArrhythmiaMedical CenterClinically SignificantFollow-UpResolutionCohortEchocardiographyMetabolismMyocardialIschemiaIndexingInsightExercise
Grant awards (10)
Unraveling The Mechanism of Heart Failure in Hypertrophic Cardiomyopathy with Exercise CMR$777,258
R01 · FY2025 · HL
Cardiac MR-Based Risk Stratification for Heart Failure and Atrial Fibrillation in HCM$675,466
R01 · FY2024 · HL
Cardiac MR-Based Risk Stratification for Heart Failure and Atrial Fibrillation in HCM$766,468
R01 · FY2023 · HL
Cardiac MR-Based Risk Stratification for Heart Failure and Atrial Fibrillation in HCM$750,428
R01 · FY2022 · HL
Cardiac MR-Based Risk Stratification for Heart Failure and Atrial Fibrillation in HCM$782,727
R01 · FY2021 · HL
Clinical and therapeutic implications of fibrosis in hypertrophic cardiomyopathy$113,490
K23 · FY2011 · HL · contact PI
Clinical and therapeutic implications of fibrosis in hypertrophic cardiomyopathy$126,172
K23 · FY2010 · HL · contact PI
Clinical and therapeutic implications of fibrosis in hypertrophic cardiomyopathy$128,895
K23 · FY2009 · HL · contact PI
Clinical and therapeutic implications of fibrosis in hypertrophic cardiomyopathy$142,395
K23 · FY2008 · HL · contact PI
Clinical and therapeutic implications of fibrosis in hypertrophic cardiomyopathy$124,347
K23 · FY2007 · HL · contact PI